Targeting aurora kinases as therapy in multiple myeloma

Area of Science:

• Oncology
• Cell Biology
• Cancer Therapeutics

Background:

• Aurora kinases are crucial for cell cycle progression and are implicated in cancer.
• Multiple myeloma (MM) exhibits genetic instability, suggesting compromised cell cycle checkpoints.
• Deficient checkpoints in MM may lead to apoptosis when mitotic machinery is damaged.

Purpose of the Study:

• To investigate the antimyeloma effects of aurora kinase inhibitors.
• To determine if these inhibitors could be a viable cancer therapy for MM.
• To explore the role of RHAMM in MM sensitivity to apoptosis.

Main Methods:

• Treatment of MM cell lines and primary samples with two aurora kinase inhibitors.
• Assessment of cell growth inhibition, apoptosis induction, and cell cycle effects.
• Evaluation of histone 3B phosphorylation as a marker of aurora kinase activity.
• Analysis of RHAMM expression and its impact on apoptosis sensitivity.

Main Results:

• Both aurora kinase inhibitors demonstrated significant growth inhibition of MM cells at nanomolar concentrations.
• MM cells treated with inhibitors underwent tetraploidy followed by apoptosis.
• Apoptosis induction correlated with reduced histone 3B phosphorylation, indicating aurora kinase inhibition.
• Overexpression of RHAMM enhanced MM cell sensitivity to apoptosis, while silencing decreased it.

Conclusions:

• Aurora kinase inhibitors show significant therapeutic potential against multiple myeloma.
• These inhibitors induce apoptosis in MM cells, offering a novel treatment strategy.
• RHAMM overexpression may identify MM patients who would benefit most from aurora kinase inhibitor therapy.